Q-omics provides the consensus-scored SNORA38B profile across patient tissues and cancer cell-line models. SNORA38B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, SNORA38B is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, SNORA38B RNA expression shows 12,760 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight PAAD, LUAD, and UVM as cancer lineages where SNORA38B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA38B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA38B survival associations across molecular data types. SNORA38B RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA38B RNA expression–survival associations across cancer types. High SNORA38B expression shows unfavorable associations in KIRC and KICH, but favorable associations in PAAD, BRCA, LUAD and STAD. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify PAAD as the clearest survival context for SNORA38B RNA expression.
This table summarizes SNORA38B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA38B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA38B shows higher tumor expression in LUAD, HNSC, LUSC, COAD, BRCA and CHOL. The LUAD box plot shows higher SNORA38B RNA expression in tumor versus normal tissue (log2 FC = +0.795, t-test p < 0.001).
This table shows molecular features associated with SNORA38B in patient tissues and cancer cell lines. In patient samples, SNORA38B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
